Eupraxia Pharmaceuticals Inc.
EPRXF · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $133,453 | $118,439 | $145,837 | $191,245 |
| - Cash | $31,905 | $48,592 | $19,342 | $33,210 |
| + Debt | $6,377 | $12,934 | $10,452 | $15,415 |
| Enterprise Value | $107,925 | $82,781 | $136,947 | $173,450 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$58 | -$50 | $0 | -$50 |
| % Margin | – | – | – | – |
| EBITDA | -$8,912 | -$8,029 | -$4,453 | -$8,574 |
| % Margin | – | – | – | – |
| Net Income | -$8,219 | -$8,150 | -$4,096 | -$6,314 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.23 | -0.28 | -0.155 | -0.25 |
| % Growth | 17.9% | -80.6% | 38% | – |
| Operating Cash Flow | -$10,539 | -$8,254 | -$879 | -$7,947 |
| Capital Expenditures | -$15 | -$9 | -$41 | -$13 |
| Free Cash Flow | -$10,553 | -$8,263 | -$920 | -$7,960 |